Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher R. Harnish has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Demands of Competitive Cycling

    by Hamish A. Ferguson, Christopher R. Harnish

    Competitive cycling encompasses events lasting from just a few seconds to many hours, days, or even weeks. Short-distance cycling is most closely associated with traditional track cycling, held on purpose-built velodromes that meet Union Cycliste Internationale (UCI) standards for dimensions and facilities suitable for international competition. Some events such as the match sprint and Keirin last under 1 minute. Others like the individual and team pursuit are intermediate endurance races of about 4 to 5 minutes, while long mass-start events such as the 50-km Madison can extend much further. World records are maintained for the events listed in Table 2.1 . Short-distance cycling also includes bicycle motocross (BMX), downhill, and cross-country eliminator disciplines, held on UCI-approved courses designed for each event. However, because course parameters vary, world records are not recognised for these competitions.

  • Open Access

    An Inconvenient Truth: Transdermal Buffering Lotions Appear to Offer No Significant Performance Improvement

    by Christopher R. Harnish, Matthew E. Holman, Michael L. Bruneau

    Background/Objectives: Transdermal bicarbonate (TBC) or carnosine (TC) have been sold as a convenient ergogenic aid, though little evidence supports these claims. The purpose of this study was to investigate if TBC or TC would improve high-intensity endurance cycling. Methods: Data were collected remotely using Zwift online platform. Fifteen cyclists completed four trials comprising five 9.1 km laps: warm-up lap, three interval laps (3 × 900 m hills, and 3 × 300 m sprints), and a 9.1 km time trial (TT) lap. A familiarization (FAM) trial followed by three randomized trials using a TBC, TC, or placebo (PLAC) lotion were completed. Trial data were assessed using general linear models to compare differences between conditions across cycling trials (p < 0.05). Results: Mean ± SD. 60 min mean max power (MMP60) was 2.9 ± 0.9 W/kg and ranged from 1.3 to 4.1 W/kg for participants. Exercise trials were 89.8 ± 17.0 min long. Laps 2–4 were ridden at 86.4 ± 7.3% and hill climbs at 131.6 ± 21.1% of MMP60, while sprints averaged 83.2 ± 17.7% of 30 s mean max power (MMP30s) and the TT ridden at 95.4 ± 8.7% of 20 min mean max power (MMP20). FAM trials were significantly lower (p < 0.05) in all power output measures, except TC sprints, and no heart rate or rating of perceived exertion differences. Similarly, there were no statistical differences in performance between any condition trials or placebo trial, but TBC hill climb power was significantly higher (p = 0.038) than TC trials. Conclusions: There are no apparent ergogenic benefits from TBC or TC during high intensity cycling performance.

  • Open Access

    An Inconvenient Truth: Transdermal Buffering Lotions Fail to Improve High-Intensity Cycling Intervals or Time Trial Performance

    by Christopher R. Harnish, Matthew E. Holman, Michael L Bruneau

    Background/Objectives: Transdermal bicarbonate (TBC) or carnosine (TC) have been sold as a convenient way to improve performance, though little evidence indicates they are ef-fective. The purpose of this study was to investigate if TBC or TC, applied as advertised, improve high-intensity endurance cycling. Methods: Using the Zwift online platform, fif-teen cyclists completed four ~50-km cycling trials that included three long sprints and three short climbs, plus a final lap time trial (TT). Trials included a familiarization (FAM) trial followed by three randomized trials using a TBC, TC, or placebo (PLAC) lotion. Trial data were analyzed using general linear models to compare differences between condi-tions across ~50-km cycling trials. Results: Mean ± SD 60-min mean max power (MMP) was 2.9 ± 0.9 W/kg and ranged from 1.3 to 4.1 W/kg. Trials were five 9.1 km laps lasting 89.8 ± 17.0 min long. Relative to MMP60, interval laps (2 – 4) were ridden at 86.4 ± 7.3% and climbs at 131.6 ± 21.1%, while sprints averaged 83.2 ± 17.7% of MMP30s. The lap 5 TT was ridden at 95.4 ± 8.7% of MMP20 and 87.5% ± 7.4% of MHR. While there were no statistical differences in performance between any treatment trial, FAM trials were significantly lower (p < 0.05) in power output measures, but not HR and RPE. Conclusions: Based on the available evidence from this and prior research, there appears to be no apparent ergogenic benefit from either TBC or TC during high intensity cycling performance.

  • Open Access

    Reliability and Validity of the Jumpster Accelerometer-Based App Compared to the Vertec When Completing a Countermovement Jump: An Examination of Field-Accessible Tools

    by Matthew E. Holman, Christopher R. Harnish

    The reliability and validity of the Jumpster app was assessed via a comparison to the Vertec during a countermovement jump. Using both tools simultaneously, 36 participants completed 100 total jump trials. Validity was assessed using correlation and tolerance analyses. Reliability was assessed using 95% predictive intervals (PI95) and tolerance limits (TL95) between the measures, comparing the standard error of the measure (SEM) and coefficients of variation (CVs) for each tool and by examining the intraclass correlation coefficient (ICC 2,K; upper and lower 95% CI) comparing both tools. The Jumpster app was weakly related to the Vertec (r = 0.24; p < 0.01). The tolerance analysis showed a moderately strong proportional bias of the Jumpster app to the Vertec (r = 0.45; p < 0.01). While all data fell within the calculated PI95 ± TL95, the Jumpster app SEM (14.7 cm) and CV (40.30%) exceeded the Vertec SEM (3.57 cm) and CV (7.22%), and the ICC was 0.55 [0.79, −0.08]. These results paired with an overall app failure rate of 15.97% indicate that the Jumpster app is neither reliable nor valid for measuring the countermovement jump.


  • Open Access

    From Progression to Regression: How Running Performance Changes for Males and Females Across the Lifespan

    by Christopher R. Harnish, Thomas C. Swensen

    Running enjoys worldwide popularity across age groups and sexes. Because of this, it serves as an excellent benchmark to compare male and female performance across the lifespan with respect to developmental progression, peak athletic performance, and age-related regression. The purpose of this review is to examine and discuss how sex and aging affect running performance in sprints, middle-distance running, and long-distance running. Based on the scientific literature and running world records from age 5–99, male running performance exceeds that of females across the lifespan, with the greatest divide beginning at puberty, which remains through old age. However, there appear to be few differences in the rate of progression in youth and the age of peak performance, but it is unclear whether the rate of decline, beginning in middle age, differs by sex and sport for record performances. Future analyses should examine changes in all running performances across the lifespan.

  • Open Access

    Response

    by Christopher R. Harnish, Gregory P. Swinand

    An abstract is unavailable. This article is available as a PDF only.

  • Open Access

    Reliability and Validity of the Jumpster accelerometer-based app compared to the Vertec when completing a countermovement jump

    by Matthew E. Holman, Christopher R. Harnish

    The reliability and validity of the Jumpster app (JA) was compared to the Vertec. Thirty-six participants completed 100 total trials using both tools simultaneously. Validity was assessed using correlation and tolerance analyses. Reliability was assessed using 95% predictive intervals (PI95) and tolerance limits (TL95) between the measures, comparing standard error of the measure (SEM) and coefficients of variation (CV) for each tool, and examining the intraclass correlation coefficient (ICC 2,K; upper and lower 95% CI) comparing both tools. The JA was weakly related to the Vertec (r = 0.24; p < 0.01). The tolerance analysis showed a moderately strong proportional bias of the JA (r = 0.45; p < 0.01). While all data fell within calculated PI95 ±TL95, the JA SEM (14.7cm) and CV (40.30%) exceeded the Vertec SEM (3.57cm) and CV (7.22%) with an ICC of 0.55 [0.79, -0.08]. These JA is neither reliable or valid.


  • Open Access

    Methodological changes to alactic time estimation fail to improve the reliability of the 15-s maximal lactate accumulation rate (V ̇Lamax) test for cycling

    by Christopher Harnish, Thomas Swensen, Deborah King

    Blood lactate is used in a variety of ways to optimize performance. Many methods to estimate various aspects of endurance performance have been proposed, including for the estimation of the maximum rate of lactate accumulation ( Lamax). The purpose of this study was to determine if two alternative methods to estimate alactic time improves the reliability of measuring Lamax. Methods: Sixteen men and twelve women completed two sprint sessions over 1-week. After a standardized 10-min warmup, subjects rested passively for 1-min whereupon a 3-µl blood sample was taken to assess baseline blood lactate concentration (BLC). Subjects then completed a 15-s sprint, and then rested passively while multiple blood samples were taken until blood lactate levels peaked. Lamax was calculated using either a standard 5-sec alactic time (Talac), or the time to peak power output (TTP). Differences and reliability across trials were analyzed using a paired-sample t-test, and coefficient of variation, Pearson correlation, and intraclass correlation (ICC), respectively; α was set at 0.05 and data are reported as mean ± sd. Results: Power (W) was similar across trials (773.0 ±143.5 vs. 758.2 ± 127.4; p = 0.333) with a CV of 4.7%. Lamax (mM.L-1.s-1) was similar across trials for Talac (0.727 ± 0.235 vs 0.682 ± 0.237; p = 0.199), and TTP (0.653 ± 0.208 vs. 0.601 ± 0.20; p = 0.201). Both methods yielded moderate reliability with CV, ICC, and R values of 16.6%, 0.636, and 0.601 for Talac and 18.1%, 0.466, and 0.47 for TTP. Conclusions: 15-s cycling sprint Lamax remains only moderately reliable even with modified Talac.


  • Open Access

    Track Cycling Sprinters’ Training Progression Over Three-Month Period

    by Hamish Ferguson, Chris Harnish, J. Geoffrey Chase

    There is a paucity of data on the progression of track cycling sprinters, and particularly the evolution of training and performance over a training cycle or season. Following our prior research showing strong relationships between sprint cycling power and endurance cycling power, we compared these relations over a 3-month period building towards a key event where maximal 30-s power was achieved. Our hypothesis is large improvements in power would come from training either for sprint maximal power or sprint maximal capacity, and this would be reflected in the data. A total of publicly available 25 datasets, over a 3-month period were used and broken into 1-month blocks. These data were plotted against the line of best fit for 30-s and 2-min power to assess if training towards the line led to better 30-s power, in contrast to focusing only on peak power. We observe the best performances came from riders who start below the 30-s vs 2-min power line of best fit, with greater capacity and ability to ride fast over a sprint series, and progressing towards focusing on specific power in the final block leading into a competition. These results support the hypothesis of combined capacity and power training based on rider-specific relationship to the line of best fit between these measures versus a strictly maximal power training focus.

  • Open Access

    Reliability of the 15-s Maximal Lactate Accumulation Rate (VLamax) Test for Cycling

    by Christopher R. Harnish, Thomas C. Swensen, Deborah King

    Background: The purpose of this study is to ascertain the reliability of two 15-s sprint cycling tests in men and women to estimate the maximum lactate accumulation rate (VLamax). Methods: Eighteen men and twelve women completed two sprint sessions over 1 week. A 10 min warm-up preceded the obtaining of a 3 µL blood lactate (BLC) sample, after which a 15 s sprint was completed; cyclists then rested passively while multiple lactate samples were taken until the levels peaked. Trial differences and reliability across trials were analyzed using a paired-sample t-test, Pearson’s correlation, Intraclass correlation (ICC), and Bland–Altman analysis with α = 0.05 for all tests; data are reported as mean ± sd. Results: Power (W) was similar across trials (773.0 ± 143.5 vs. 758.2 ± 127.4; p = 0.333) and the coefficient of variation (CV) of 4.7%. VLamax (mM·L−1·s−1) was similar (0.673 ± 0.024 vs. 0.635 ± 0.237; p = 0.280), but only moderately reliable across trials with CV, ICC, and R values of 18.6%, 0.661, and 0.67, respectively. Pre-BLC and peak BLC CV were 45.6 and 23.3%, respectively. Conclusions: A 15 s VLamax cycling sprint is moderately reliable, possibly affected both by the lactate measurement and other variables used in the calculation. More research may offer ways to improve reliability.